|
Kala Pharmaceuticals, Inc. (KALA) Avaliação DCF
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Kala Pharmaceuticals, Inc. (KALA) Bundle
Explore as perspectivas financeiras da Kala Pharmaceuticals, Inc. (KALA) com nossa calculadora DCF amigável! Digite suas projeções de crescimento, margens e despesas para calcular o valor intrínseco da Kala Pharmaceuticals, Inc. (KALA) e refine sua abordagem de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.1 | 6.4 | 11.2 | 3.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 4.74 | 76.67 | -65.37 | -100 | -20.99 | -20.99 | -20.99 | -20.99 | -20.99 |
| EBITDA | -83.3 | -92.9 | -132.0 | -36.7 | -36.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -1370.61 | -1460.26 | -1173.99 | -942.86 | 100 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 2.6 | 2.8 | 2.3 | .9 | .3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 43.07 | 44.58 | 20.18 | 22.1 | 100 | 45.98 | 45.98 | 45.98 | 45.98 | 45.98 |
| EBIT | -85.9 | -95.7 | -134.2 | -37.6 | -36.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -1413.68 | -1504.84 | -1194.17 | -964.95 | 100 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 85.4 | 153.5 | 92.1 | 70.5 | 50.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 13.1 | 9.9 | 17.5 | 6.5 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 215.64 | 154.89 | 155.29 | 166.93 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | 4.6 | 5.2 | 8.6 | 7.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 76.52 | 82.19 | 76.86 | 197.12 | 100 | 87.11 | 87.11 | 87.11 | 87.11 | 87.11 |
| Accounts Payable | 2.5 | 1.7 | 2.8 | 2.3 | .9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 41.46 | 27.1 | 24.72 | 60.35 | 100 | 50.73 | 50.73 | 50.73 | 50.73 | 50.73 |
| Capital Expenditure | -1.3 | -1.9 | -.9 | -.3 | -.6 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -21.98 | -30.52 | -7.88 | -8.04 | 100 | -13.69 | -13.69 | -13.69 | -13.69 | -13.69 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -92.8 | -102.8 | -143.3 | -.2 | -36.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -106.8 | -100.0 | -151.9 | 11.9 | -24.2 | -.7 | .0 | .0 | .0 | .0 |
| WACC, % | 12.51 | 12.51 | 12.51 | 1.63 | 12.51 | 10.33 | 10.33 | 10.33 | 10.33 | 10.33 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -15 | |||||||||
| Equity Value | 14 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 5.74 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real KALA financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Kala Pharmaceuticals' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- Customizable Financial Inputs: Adjust essential parameters such as revenue projections, operating margins, and research & development expenses.
- Instant DCF Valuation: Automatically computes intrinsic value, net present value (NPV), and additional financial metrics.
- High-Precision Analysis: Leverages Kala Pharmaceuticals' actual financial data for accurate valuation results.
- Effortless Scenario Testing: Easily evaluate various assumptions and analyze different financial outcomes.
- Efficiency Booster: Streamline the valuation process by avoiding the creation of intricate financial models from the ground up.
How It Works
- Download: Get the pre-configured Excel file featuring Kala Pharmaceuticals, Inc. (KALA) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results instantly.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose This Calculator for Kala Pharmaceuticals, Inc. (KALA)?
- Accurate Data: Utilize real Kala Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations remove the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: An intuitive design and clear, step-by-step guidance ensure accessibility for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing investments in Kala Pharmaceuticals, Inc. (KALA).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Kala Pharmaceuticals, Inc. (KALA).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Kala Pharmaceuticals, Inc. (KALA) are valued in the marketplace.
What the Template Contains
- Preloaded KALA Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.